Pedro José Fernández Esparcia, Andrés González García, Daniela Baracaldo Santamaría, Carmen Moreno García Del Real, María Asunción Ballester Martínez
{"title":"Apremilast in Persistent Mucocutaneous Erythema Multiforme: A Case Report - Expanding the Therapeutic Evidence.","authors":"Pedro José Fernández Esparcia, Andrés González García, Daniela Baracaldo Santamaría, Carmen Moreno García Del Real, María Asunción Ballester Martínez","doi":"10.1159/cde/abvag024","DOIUrl":"https://doi.org/10.1159/cde/abvag024","url":null,"abstract":"<p><strong>Introduction: </strong>Persistent erythema multiforme (EM) is a rare and poorly defined variant of EM characterized by prolonged mucocutaneous involv ent and limited therapeutic options. Evidence regarding its management is scarce. Apremilast has shown efficacy in isolated reports of other EM subtypes, suggesting a potential role in refractory cases.</p><p><strong>Case presentation: </strong>We present the case of a 45-year-old woman with recurrent EM who subsequently developed prolonged, continuously active mucocutaneous disease lasting 6 years. The disease was refractory or intolerant to multiple therapies, including antivirals, corticosteroids, colchicine, dapsone, hydroxychloroquine, azathioprine, and biologic agents. Extensive clinical, histopathological, immunological, and systemic evaluation supported the diagnosis of EM and did not identify an underlying condition. Apremilast (30 mg twice daily) was initiated resulting in progressive improvement, with complete resolution of oral involvement within 3 months. After 1 year of follow-up, the patient remains in sustained clinical remission with good tolerability and no significant adverse effects.</p><p><strong>Conclusion: </strong>This case adds to the limited evidence supporting the potential use of apremilast in difficult-to-treat EM with prolonged mucocutaneous activity. Although the rapid and sustained response observed in this patient is encouraging, further studies are needed to determine the efficacy, optimal treatment duration, and long-term safety of apremilast in this setting.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"762-768"},"PeriodicalIF":0.7,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Refractory Chronic Eosinophilic Annular Erythema Successfully Treated with Dupilumab: A Case Report.","authors":"Avery H Seward, Robert J Pariser","doi":"10.1159/cde/abvag023","DOIUrl":"https://doi.org/10.1159/cde/abvag023","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic annular erythema (EAE) is a rare eosinophilic skin condition that lacks a well-established treatment plan. It is characterized by annular, erythematous, indurated plaques which may be asymptomatic or pruritic. Histologically, EAE shares features with Wells syndrome (WS), including a dense dermal eosinophilic infiltrate, which has led to varying opinions as to whether they are distinct entities or lie on a clinical spectrum. We report a case of a woman with a well-documented 26-year history of refractory EAE that ultimately responded to dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13.</p><p><strong>Case presentation: </strong>The patient initially presented at age 13 with a pruritic eruption composed of arcuate plaques with raised borders, trailing scale, and prominent post-inflammatory hyperpigmentation involving the trunk and extremities. Skin biopsies performed in 2000, 2004, and 2021 demonstrated a superficial and deep perivascular and interstitial eosinophilic infiltrate. The first two biopsies showed eosinophil degranulation and flame figures, while the third remained consistent with EAE without flame figures. Laboratory evaluation revealed persistent peripheral eosinophilia (14-22%) without identifiable underlying systemic disease. Over 26 years of follow-up by a single clinician, the patient failed numerous therapies, including topical and systemic corticosteroids, calcineurin inhibitors, antihistamines, antibiotics, antifungals, imiquimod, dapsone, hydroxychloroquine, phototherapy, upadacitinib, and omalizumab, with only transient or minimal benefit. In July 2025, treatment with dupilumab was initiated using a 600 mg loading dose followed by 300 mg every other week. The patient experienced significant improvement in pruritus and marked reduction in erythema and induration of active lesions, with no new lesions developing over 9 months of follow-up.</p><p><strong>Conclusion: </strong>This case represents successful treatment with dupilumab of longstanding EAE with overlapping histologic features of WS and persistent eosinophilia and adds to the growing evidence that EAE and WS may lie on a clinical spectrum. The patient's response supports a role for IL-4/IL-13-mediated type 2 inflammation in the pathogenesis of EAE and further suggests that dupilumab may be an effective therapeutic option for refractory, chronic EAE.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"793-799"},"PeriodicalIF":0.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report.","authors":"Ayane Seko, Shimpei Nagai, Makiko Hino, Noriko Takatsuji, Terumi Shirane, Moito Iijima, Yoshihisa Hattori, Takashi Kurahashi","doi":"10.1159/cde/abvag021","DOIUrl":"https://doi.org/10.1159/cde/abvag021","url":null,"abstract":"<p><strong>Introduction: </strong>Bullous pemphigoid (BP) is a rare but clinically significant cutaneous immune-related adverse event (irAE) of immune checkpoint inhibitor (ICI) therapy. It is most often described during treatment of melanoma, lung cancer, and renal cell carcinoma, whereas reports in gynecologic oncology, and specifically during lenvatinib plus pembrolizumab (LP) therapy, remain scarce.</p><p><strong>Case presentation: </strong>A 53-year-old Japanese woman with International Federation of Gynecology and Obstetrics (FIGO) stage IA endometrioid carcinoma underwent hysterectomy followed by adjuvant paclitaxel-carboplatin. Peritoneal recurrence occurred 30 months later. After paclitaxel-carboplatin rechallenge and subsequent progression, LP therapy was initiated. At 38 weeks (cycle 9), erythema progressed to widespread tense bullae on the trunk and extremities with hard-palate erosion. Serum anti-BP180 antibody was markedly elevated (115.4 U/mL; reference: <9.0). Skin biopsy showed subepidermal cleft formation with an eosinophil-rich infiltrate. Direct immunofluorescence (DIF) was negative; nevertheless, ICI-related BP (Common Terminology Criteria for Adverse Events [CTCAE] v5.0, grade 3) was diagnosed on the basis of clinical, serological, and histopathological findings. LP therapy was discontinued and prednisolone 90 mg/day (approximately 1 mg/kg) was started, achieving rapid clinical improvement and antibody decline. Pembrolizumab was permanently discontinued, and lenvatinib monotherapy was resumed 7 weeks later under tapering steroids. Dose reduction was required for hand-foot syndrome, but no BP recurrence has been observed.</p><p><strong>Conclusion: </strong>BP should be considered in patients who develop tense bullae during LP therapy, even when DIF is negative. In severe cases with mucosal involvement, selective discontinuation of pembrolizumab while continuing lenvatinib monotherapy may represent a reasonable individualized strategy. As LP therapy expands in gynecologic oncology, recognition and multidisciplinary management of rare cutaneous irAEs by dermatologists is increasingly important.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"785-792"},"PeriodicalIF":0.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Basit Khan, Aniebiot Abasi Udofia, Oluwaseyi Ayodeji Akinseinde, Gerald Saldanha
{"title":"A Case Report Outlining Polyarteritis Nodosa: A Cutaneous Conundrum in a Haemodialysis Patient.","authors":"Basit Khan, Aniebiot Abasi Udofia, Oluwaseyi Ayodeji Akinseinde, Gerald Saldanha","doi":"10.1159/cde/abvag020","DOIUrl":"https://doi.org/10.1159/cde/abvag020","url":null,"abstract":"<p><strong>Introduction: </strong>Skin disorders are quite common with haemodialysis patients due to vascular, neurological, and immune-mediated risk factors intrinsically connected to chronic kidney disease and the dialysis process.</p><p><strong>Case presentation: </strong>We report a case of cutaneous polyarteritis nodosa in a middle-aged man with painful leg ulcerations. Initially suspected to be a life-threatening condition such as calciphylaxis or severe cellulitis, the diagnosis was confirmed through a skin biopsy.</p><p><strong>Conclusion: </strong>This case highlights the complexities of diagnosis and presents a concept map illustrating the relationships between chronic kidney disease, dialysis, and skin disorders.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"776-784"},"PeriodicalIF":0.7,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Electron Beam Therapy for Perforating Granuloma Annulare: A Case Report.","authors":"Shuo Li, Jinli Liu, Jinke Ma, Jun Tang","doi":"10.1159/cde/abvag010","DOIUrl":"https://doi.org/10.1159/cde/abvag010","url":null,"abstract":"<p><strong>Introduction: </strong>Perforating granuloma annulare (PGA) is a rare benign inflammatory dermatosis, accounting for merely 5% of all granuloma annulare (GA) cases. Standardized treatment regimens for refractory PGA are still unavailable, and there are sparse published reports evaluating electron beam therapy (EBT) for this specific skin disease.</p><p><strong>Case presentation: </strong>We describe a 66-year-old Chinese woman with a 5-year history of refractory PGA affecting the right forearm, who showed no response to multiple conventional therapies. The patient initially received an EBT-based multimodal regimen, and subsequent EBT monotherapy was administered for residual lesions. After treatment, remarkable clinical improvement with near-complete resolution of PGA lesions was obtained. No disease recurrence or radiation-related adverse events were detected over the 10-month follow-up.</p><p><strong>Conclusion: </strong>Low-dose superficial EBT may be a promising, well-tolerated individualized therapeutic alternative for refractory PGA. Our findings provide supplementary real-world clinical evidence for research on this rare inflammatory dermatosis. Further clinical investigations are needed to validate the long-term efficacy of EBT and establish unified treatment protocols for PGA.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"725-730"},"PeriodicalIF":0.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Adult Diagnosis of Infantile Hemangioma with Minimal or Arrested Growth of the Heel: A Case report.","authors":"Mohammed Shanshal, Emily Moon, Georgios Kallikas","doi":"10.1159/cde/abvag008","DOIUrl":"https://doi.org/10.1159/cde/abvag008","url":null,"abstract":"<p><strong>Introduction: </strong>Infantile hemangioma with minimal or arrested growth (IH-MAG) is a recognized subtype of infantile hemangioma that presents as a predominantly flat telangiectatic or reticular lesion with little or no postnatal proliferation and may be mistaken for capillary malformation or other superficial vascular anomalies.</p><p><strong>Case presentation: </strong>We report a 22-year-old woman with a long-standing asymptomatic reticular vascular patch on the posterolateral heel, reported by family to have been present since infancy and stable over time. Punch biopsy showed a predominantly fibrosed dermis containing sparse small vascular profiles, while GLUT1 immunohistochemistry highlighted lesional endothelial staining. Taken together, the clinicopathologic findings supported infantile hemangioma lineage and favored IH-MAG, likely reticular type.</p><p><strong>Conclusion: </strong>IH-MAG may persist into adulthood as a subtle acral lesion in which capillary malformation is the main clinical mimic. Accurate diagnosis, supported by clinicopathologic correlation, is clinically relevant because it identifies a lesion expected to remain stable and not require active intervention.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"720-724"},"PeriodicalIF":0.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natsumi Norikawa, Misaki Kusano, Aki Honda, Toshiyuki Yamamoto
{"title":"Six Cases of Pemphigoid Nodularis during Treatment with Dipeptidyl Peptidase-4 Inhibitors.","authors":"Natsumi Norikawa, Misaki Kusano, Aki Honda, Toshiyuki Yamamoto","doi":"10.1159/000552572","DOIUrl":"10.1159/000552572","url":null,"abstract":"<p><strong>Introduction: </strong>We investigated 6 cases of pemphigoid nodularis under treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors.</p><p><strong>Case representation: </strong>In 3 cases, only nodules were observed at the initial presentation, but bullous lesions appeared during the course of the disease. All patients had diabetes mellitus and were taking DPP-4 inhibitors from 1 to 1.5 years. Anti-BP180Nc16a antibodies were positive in 3 cases, and low or negative in 3 cases. Full-length BP180 antibodies were analyzed in 2 of the 6 cases and were positive in both. Since patients with diabetes mellitus occasionally develop prurigo nodularis, it is important not to misdiagnose pemphigoid nodularis as prurigo nodularis.</p><p><strong>Conclusion: </strong>There are few reports of pemphigoid nodularis under DPP-4 inhibitors. It should be noted that not only bullous pemphigoid but also pemphigoid nodularis can be induced by DPP-4 inhibitors.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"675-683"},"PeriodicalIF":0.7,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623351/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Madyson Burtner, Allison Goldenstein, David Cleaver, Jonathan Cleaver
{"title":"Dupilumab for Pediatric Linear Bullous Dermatosis: A Case Report and Literature Review.","authors":"Madyson Burtner, Allison Goldenstein, David Cleaver, Jonathan Cleaver","doi":"10.1159/cde/abvag007","DOIUrl":"https://doi.org/10.1159/cde/abvag007","url":null,"abstract":"<p><strong>Introduction: </strong>Linear IgA bullous dermatosis (LABD) is a rare autoimmune subepidermal blistering disease characterized by linear IgA deposition at the dermo-epidermal junction. While dapsone is the established first-line therapy, its use can be limited by the need for glucose-6-phosphate dehydrogenase screening and potential adverse effects. Novel treatments targeting the Th2 inflammatory pathway, such as dupilumab, are emerging as potential options.</p><p><strong>Case presentation: </strong>We present the case of a 17-year-old male with a 5-year history of pruritic vesicles and papules affecting 20% of his body surface area. The patient had failed multiple treatments, including high-potency topical steroids and oral prednisone tapers. Due to a preference to avoid dapsone and its associated monitoring, the patient was started on dupilumab (600 mg loading dose, followed by 300 mg every 2 weeks). Following initiation, the patient experienced a dramatic reduction in pruritus, with his itch scale improving from 9/10 to 1/10. Although active vesicle formation persisted, the patient reported high satisfaction and clinical improvement in lesion burden.</p><p><strong>Conclusion: </strong>This case adds to the limited but growing body of evidence supporting the use of dupilumab in pediatric LABD. While it may not always result in lesion clearance as monotherapy, dupilumab's ability to significantly alleviate the debilitating pruritus associated with LABD makes it a compelling therapeutic alternative, particularly in refractory cases or when conventional systemic therapies are deferred. Further research is needed to determine the long-term efficacy and optimal positioning of dupilumab in the LABD treatment algorithm.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"714-719"},"PeriodicalIF":0.7,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah L Spaulding, Jason R McFadden, Jeffrey M Cohen, Caroline A Nelson, William Damsky
{"title":"Dupilumab-Responsive Grover Disease with Concomitant Eczematous Dermatitis: A Case Report and Review of 27 Cases.","authors":"Sarah L Spaulding, Jason R McFadden, Jeffrey M Cohen, Caroline A Nelson, William Damsky","doi":"10.1159/cde/abvag019","DOIUrl":"https://doi.org/10.1159/cde/abvag019","url":null,"abstract":"<p><strong>Introduction: </strong>Grover disease (GD) is a pruritic eruption with no reliably effective treatment. Emerging evidence suggests that type 2 (Th2) inflammation may contribute to GD pathogenesis. Accordingly, dupilumab has emerged as a potential therapy for recalcitrant GD. The clinical features that correlate with response remain incompletely defined; however, atopic history has been proposed as one potential marker.</p><p><strong>Case presentation: </strong>A 68-year-old man with biopsy-confirmed GD and concomitant late-onset eczematous dermatitis, but no prior atopic history, presented with severe truncal pruritus refractory to topical and antihistamine therapies. After starting dupilumab, pruritus improved within 1 day, and his GD lesions had fully resolved by 3 months.</p><p><strong>Conclusion: </strong>Our case expands the spectrum of patients with GD who may benefit from dupilumab, lends further support for the role of Th2 cytokines in GD pathogenesis, and highlights eczematous inflammation as a feature warranting further study. Prospective studies incorporating clinical features and tissue biomarkers are needed to better identify patients with GD who are most likely to benefit from dupilumab.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"769-775"},"PeriodicalIF":0.7,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rie Hyobu, Kenichiro Mae, Aya Takahashi, Tatsuo Maeda, Kazutoshi Harada
{"title":"Toxic Epidermal Necrolysis Secondary to Nodal T-Follicular Helper Cell Lymphoma, not Otherwise Specified: A Case Report.","authors":"Rie Hyobu, Kenichiro Mae, Aya Takahashi, Tatsuo Maeda, Kazutoshi Harada","doi":"10.1159/cde/abvag018","DOIUrl":"https://doi.org/10.1159/cde/abvag018","url":null,"abstract":"<p><strong>Introduction: </strong>Nodal T-follicular helper cell lymphoma (nTFHL) is a rare subtype of peripheral T-cell lymphoma in which cutaneous manifestations occur in approximately half the patients.</p><p><strong>Case presentation: </strong>We report herein a case of toxic epidermal necrolysis (TEN) in a 62-year-old, male, Japanese patient with nTFHL, not otherwise specified. The patient experienced the development of rapidly progressive, erythematous plaques with blistering and erosion involving more than 30% of the body surface area. Histopathological examination of the skin revealed total epidermal necrosis without lymphoma cell infiltration while immunohistochemical analysis demonstrated depletion of FOXP3-positive cells. The TEN was successfully treated with systemic corticosteroid therapy, plasma exchange, and intravenous immunoglobulin. Although EBER-positive B cells in lymph nodes and EBV DNAemia were detected, their contribution to the TEN remains unclear.</p><p><strong>Conclusion: </strong>This case expands the spectrum of severe, cutaneous manifestations associated with nTFHL and suggests that a reduction of regulatory T cells, previously reported in lymph nodes, may also occur locally in the skin and contribute to the development of cutaneous manifestations.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"18 1","pages":"738-743"},"PeriodicalIF":0.7,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}